Therapeutic angiogenesis with the use of vascular endothelial growth factor 165 gene in the myocardium of miniature swine

( views:, downloads: )
Journal Title:
Volume 53, Issue 03, 2001
Key Word:


  • [1]Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med, 1999, 77:527~543.
  • [2]Mark CA, Budenbender KT, Magovern CJ et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion.J Vasc Surg, 1998, 27:699 ~ 709.
  • [3]Mark CA, Patel SR, Schwarz EA et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg, 1998,115:168~177.
  • [4]Alexander MY, Webster KA, Mcdonald PH et al. Gene transfer and models of gene therapy for the myocardikum, Clin Exp Phamacol Physiol, 1999, 26:661 ~668.
  • [5]Losordo DW, Vale PR, Symes JF et al. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation, 1998, 98:2800~2804.
  • [6]Yang KTA, Chen HD. Evaluation of global and regional left ventricular function using technetium-99m sestamibi ECGgated single-photon emission tomography. Eur J Nucl Med, 1998, 25:515 ~ 521.
  • [7]Tadamura E, Kudoh T, Motooka M et al. Assessment of regional and global left ventricular function by reinjection Tl201 and rest Tc-99m sestamibi ECG-gated SPECT. J Am Call Cardiol, 1999, 33(4) :991~997.
  • [8]Rentrop KP, Coben M, Blanke H et al. Change in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects J Am Coll Cardiol, 1985,5:587~ 592.
  • [9]Yamagishi S, Yonekura H, Yamamoto Y et al. Vascnlar endothelial growth factor acts as a pericyte mitogen under hypoxic conditions.Lab Invest, 1999, 79:501 ~ 509.
  • [10]Sirois MG, Edelman ER. VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor.Am J Physiol,1997, 272:H2746~ H2756.
  • [11]Magovern CJ, Mark CA, Zhang J et al. Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther,1997, 8(2) :215 ~ 227.
  • [12]White FC, Carroll SM, Magent A et al. Coronary collateral development in swine after coronary artery occlusion. Circ Res, 1992, 71:1490~1500.
  • [13]O'Riordan CR, Lachapelle A, Delgado C et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo, Hum Gen Ther,1999, 10:1349~ 1358.
  • [14]Li J, Brown LF, Hibbert MG et al.VEGF, flk-1,and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol, 1996, 270:H1803~ H1811.
  • [16]Shinohara K. The expression and the role of vascular endothelial growth factor in human normal and myocardial infarcted heart. Hokkaido Igaku Zasshi, 1994, 69(4) :978 ~ 993.
  • [17]Inoue M, Itoh H, Ueda M et al. Vascular endothelial growth factor expression in human coronary atherosclerotic lesions:possible pathophysiological significance of VEGF in progression of atherosclerosis.Circ, 1998, 98:2108~2116.
  • [18]Patel SR, Lee LY, Mark CA et al.. Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121. Hum Gen Ther, 1999, 10:1331 ~ 1348.
  • [19]Rosengart TK, Leonard YL, SHailen KP et al. Six-month assessment of a phase Ⅰ trial of angiogenic gene therapy for the treatment of coronary artery disese using direct intramyocardial administration of an adenovirus vector expressing the vascular endothelial growth factor 121 cDNA. Ann Surg, 1999,230(4) :466 ~ 472.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615